| Date |
Title |
Rating |
| 2009-12-31 |
FDA evaluates Phase III randomized trial in acute myeloid leukemia |
None |
| 2009-12-30 |
Santarus submits rifamycin SV MMX IND to the FDA |
None |
| 2009-12-30 |
Phase 3 trial of figitumumab discontinued by Pfizer |
None |
| 2009-12-29 |
Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer |
None |
| 2009-12-29 |
Promising results from Soligenix' RiVax vaccine against ricin toxin |
None |
| 2009-12-28 |
SVA submits the first clinical trial application for HFMD vaccine in China |
None |
| 2009-12-24 |
SemBioSys Genetics' Apo AI(Milano) program progress update |
None |
| 2009-12-24 |
Forest Laboratories acquires additional rights to NXL 104 beta-lactamase inhibitor |
None |
| 2009-12-24 |
Merck discontinues MK-1903 niacin receptor agonist development program with Arena Pharmaceuticals |
5 |
| 2009-12-23 |
Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST |
None |
| 2009-12-23 |
Positive results from Alimera Sciences' Iluvien FAME trial for DME |
4.5 |
| 2009-12-23 |
Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo |
None |
| 2009-12-23 |
Compugen, Pfizer enter into multi-target collaboration |
None |
| 2009-12-23 |
ARCA biopharma submits Gencaro trial protocol for review under the FDA’s SPA process |
None |
| 2009-12-23 |
US Phase 2 clinical trial of RVX-208 commenced by Resverlogix |
None |
| 2009-12-22 |
Eritoran well tolerated in Phase II trial for severe sepsis |
None |
| 2009-12-22 |
Effectiveness of Genfit’s GFT505 clinical drug candidate questioned |
None |
| 2009-12-22 |
Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA |
None |
| 2009-12-22 |
DSM BioSolutions to manufacture Mayoly Spindler's 'MS1819' lipase biotherapeutic |
None |
| 2009-12-22 |
LEO Pharma announces positive results for two Phase III AK clinical trials |
None |
| 2009-12-21 |
Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported |
None |
| 2009-12-21 |
Oxford Finance to provide Titan Pharmaceuticals a $3M term loan |
None |
| 2009-12-21 |
Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study |
None |
| 2009-12-21 |
Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV |
5 |
| 2009-12-21 |
Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy |
None |
| 2009-12-21 |
OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries |
3 |
| 2009-12-21 |
CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial |
None |
| 2009-12-21 |
Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor |
None |
| 2009-12-21 |
Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study |
2.3 |
| 2009-12-21 |
Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial |
None |
| 2009-12-21 |
Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention |
None |
| 2009-12-21 |
Preliminary results from Phase III study of afamelanotide in EPP announced |
None |
| 2009-12-18 |
Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials |
None |
| 2009-12-18 |
U.S. health officials announce shift in focus of prep trial in Botswana |
None |
| 2009-12-18 |
PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study |
None |
| 2009-12-18 |
Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV |
None |
| 2009-12-18 |
Initial data from REVLIMID Phase III trial in multiple myeloma patients announced |
None |
| 2009-12-18 |
Phase 2 clinical study of STA-9090 in NSCLC initiated |
None |
| 2009-12-18 |
ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus |
None |
| 2009-12-17 |
Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67 |
None |
| 2009-12-17 |
Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences |
None |
| 2009-12-17 |
AlphaRx, Venturepharm sign supply agreement for ARX1088's API |
None |
| 2009-12-17 |
Positive results from DURECT's Phase IIb POSIDUR clinical trial for post-surgical pain |
None |
| 2009-12-17 |
Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts |
None |
| 2009-12-17 |
Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV |
None |
| 2009-12-17 |
BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint |
None |
| 2009-12-17 |
Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial |
None |
| 2009-12-17 |
Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients |
2 |
| 2009-12-17 |
Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced |
None |
| 2009-12-16 |
Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals |
None |
| 2009-12-16 |
NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound |
1 |
| 2009-12-16 |
Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals |
None |
| 2009-12-16 |
ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA |
None |
| 2009-12-16 |
Advanced Life Sciences Holdings' Restanza promising against tularemia |
None |
| 2009-12-16 |
Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine |
None |
| 2009-12-16 |
Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study |
None |
| 2009-12-16 |
Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer |
None |
| 2009-12-16 |
Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects |
None |
| 2009-12-16 |
Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression |
None |
| 2009-12-16 |
Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial |
None |
| 2009-12-16 |
Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected |
5 |
| 2009-12-16 |
Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research |
None |
| 2009-12-16 |
ThromboGenics completes enrollment in second microplasmin Phase III trial |
None |
| 2009-12-15 |
DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment |
None |
| 2009-12-15 |
BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP |
None |
| 2009-12-15 |
Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001 |
None |
| 2009-12-15 |
Positive results from study comparing exenatide once weekly to BYETTA |
3 |
| 2009-12-15 |
Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody |
None |
| 2009-12-15 |
Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel |
4 |
| 2009-12-15 |
University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer |
None |
| 2009-12-15 |
Encouraging results from DAVANAT in combination with chemotherapies and biologics |
None |
| 2009-12-15 |
Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis |
None |
| 2009-12-15 |
Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore |
None |
| 2009-12-15 |
QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients |
None |
| 2009-12-15 |
Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin |
None |
| 2009-12-15 |
Molecular Partners closes its CHF 46 million Series B equity investment round |
None |
| 2009-12-15 |
Update on new clinical developments and other initiatives related to Ceplene |
None |
| 2009-12-15 |
Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified |
None |
| 2009-12-15 |
Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints |
None |
| 2009-12-15 |
Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented |
None |
| 2009-12-14 |
Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers |
3.5 |
| 2009-12-14 |
Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer |
5 |
| 2009-12-14 |
AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection |
None |
| 2009-12-14 |
Pfizer announces results from studies evaluating neratinib |
None |
| 2009-12-14 |
Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented |
None |
| 2009-12-14 |
Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin |
5 |
| 2009-12-14 |
Combination therapy improves overall survival in women with advanced breast cancer |
None |
| 2009-12-14 |
Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495 |
None |
| 2009-12-14 |
Genentech announces positive results from Phase II study of T-DM1 |
None |
| 2009-12-14 |
Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839 |
None |
| 2009-12-14 |
ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data |
None |
| 2009-12-13 |
Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics |
None |
| 2009-12-13 |
Positive interim results of ARRY-380 in Phase 1 trial announced |
None |
| 2009-12-13 |
Clinical trial of 2009 H1N1 influenza vaccine |
None |
| 2009-12-12 |
Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced |
None |
| 2009-12-12 |
Phase 1 clinical trial of iCo-007 demonstrates positive safety profile |
None |
| 2009-12-11 |
Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences |
None |
| 2009-12-11 |
Zevalin clinical data presented at 2009 ASH meeting |
None |
| 2009-12-11 |
Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics |
1 |
| 2009-12-11 |
Pfizer announces IES analysis of Aromasin in breast cancer recurrence |
None |
| 2009-12-11 |
ThromboGenics initiates Phase II trial of microplasmin for wet AMD |
None |
| 2009-12-11 |
Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA |
None |
| 2009-12-11 |
Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients |
None |
| 2009-12-11 |
Initiation of multi-national Phase III study of Stimuvax announced |
1 |
| 2009-12-11 |
DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies |
None |
| 2009-12-11 |
Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer |
None |
| 2009-12-10 |
Positive results from BioAlliance Pharma's acyclovir Lauriad phase III trial |
None |
| 2009-12-10 |
FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study |
None |
| 2009-12-10 |
DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA |
None |
| 2009-12-10 |
Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia |
None |
| 2009-12-10 |
Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC |
1 |
| 2009-12-10 |
Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA |
5 |
| 2009-12-10 |
Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals |
None |
| 2009-12-10 |
Fourth-quarter and full year fiscal 2009 results announced by Biodel |
None |
| 2009-12-10 |
Immune-based treatment promising for AD |
None |
| 2009-12-10 |
Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8 |
None |
| 2009-12-10 |
Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences |
None |
| 2009-12-10 |
Initiation of dose-finding study to evaluate safety and efficacy of MP4OX treatment |
None |
| 2009-12-10 |
Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated |
None |
| 2009-12-09 |
Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced |
None |
| 2009-12-09 |
Roche to present data on its Herceptin, Avastin and T-DM1 studies at CTRC-AACR Symposium |
None |
| 2009-12-09 |
RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352 |
None |
| 2009-12-09 |
Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment |
None |
| 2009-12-09 |
Osteologix to file an European Marketing Application for its NB S101 strontium therapy |
None |
| 2009-12-09 |
Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented |
None |
| 2009-12-09 |
Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences |
5 |
| 2009-12-09 |
Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML |
None |
| 2009-12-09 |
VERTICAL Phase II trial results for NHL released |
5 |
| 2009-12-09 |
Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma |
None |
| 2009-12-09 |
Memgen announces positive clinical data of ISF35 with chemotherapy |
None |
| 2009-12-09 |
TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer |
None |
| 2009-12-09 |
University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle |
None |
| 2009-12-09 |
Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented |
None |
| 2009-12-09 |
Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study |
None |
| 2009-12-09 |
Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience |
None |
| 2009-12-09 |
Phase II clinical trial results of Doxorubicin Transdrug announced |
None |
| 2009-12-09 |
GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma |
None |
| 2009-12-09 |
Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients |
None |
| 2009-12-08 |
Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented |
None |
| 2009-12-08 |
Micromet presents final data from its blinatumomab Phase 2 study for ALL |
None |
| 2009-12-08 |
The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children |
None |
| 2009-12-08 |
Updated data from Allos Therapeutics' ongoing FOLOTYN study |
None |
| 2009-12-08 |
Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia |
3 |
| 2009-12-08 |
Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint |
None |
| 2009-12-08 |
Interim data from Geron's GRNVAC1 phase II trial for AML presented |
None |
| 2009-12-08 |
Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma |
None |
| 2009-12-08 |
Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting |
None |
| 2009-12-08 |
Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma |
None |
| 2009-12-08 |
Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma |
None |
| 2009-12-08 |
Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced |
5 |
| 2009-12-08 |
Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS |
5 |
| 2009-12-08 |
Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients |
None |
| 2009-12-08 |
SOLESTA pivotal study meets primary endpoints for fecal incontinence treatment |
None |
| 2009-12-08 |
Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL |
None |
| 2009-12-08 |
Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML |
None |
| 2009-12-08 |
Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy |
None |
| 2009-12-08 |
Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations |
None |
| 2009-12-08 |
ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma |
None |
| 2009-12-08 |
Gentium presents evaluation results of Defibrotide for VOD at the ASH conference |
None |
| 2009-12-08 |
Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients |
None |
| 2009-12-08 |
Galapagos NV receives milestone payment to initiate Phase I clinical trial of GLPG0555 drug |
None |
| 2009-12-08 |
Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients |
None |
| 2009-12-08 |
Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009 |
None |
| 2009-12-08 |
PolyMedix to present data on its heptagonist compounds |
None |
| 2009-12-08 |
Amgen announces results from first Phase 1/2 study of Nplate |
None |
| 2009-12-08 |
CAM314 randomized Phase 3 clinical trial results released |
5 |
| 2009-12-08 |
Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported |
None |
| 2009-12-08 |
Phase II clinical trial results reveal positive effects of omacetaxine against CML |
None |
| 2009-12-08 |
Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting |
None |
| 2009-12-08 |
Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients |
None |
| 2009-12-08 |
Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA |
None |
| 2009-12-08 |
Phase 1 study results of TRU-016 in patients with CLL announced |
None |
| 2009-12-07 |
Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced |
None |
| 2009-12-07 |
Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported |
None |
| 2009-12-07 |
New data from Allos Therapeutics' FOLOTYN trial for PTCL |
None |
| 2009-12-07 |
Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented |
None |
| 2009-12-07 |
Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients |
5 |
| 2009-12-07 |
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting |
None |
| 2009-12-07 |
Synta Pharmaceuticals announces study results of elesclomol |
None |
| 2009-12-07 |
Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH |
None |
| 2009-12-07 |
Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin |
None |
| 2009-12-07 |
Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting |
None |
| 2009-12-07 |
UCB presents data on Vimpat AED at AES meeting |
None |
| 2009-12-07 |
Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology |
None |
| 2009-12-07 |
Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin |
None |
| 2009-12-07 |
Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting |
None |
| 2009-12-07 |
J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism |
None |
| 2009-12-07 |
Positive clinical data from Phase II study of elacytarabine in patients with AML reported |
None |
| 2009-12-07 |
Updated results from phase III EXTEND clinical trial of pixantrone released |
None |
| 2009-12-07 |
Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful |
None |
| 2009-12-07 |
ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting |
None |
| 2009-12-07 |
Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced |
None |
| 2009-12-07 |
Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics |
None |
| 2009-12-07 |
Researchers explore optimal induction therapies for managing blood cancer |
None |
| 2009-12-07 |
VELCADE based regimens are cost-effective for payers and patients, finds study |
None |
| 2009-12-07 |
New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported |
None |
| 2009-12-07 |
Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris |
None |
| 2009-12-07 |
Amgen announces results from three studies on the safety and efficacy of Nplate |
None |
| 2009-12-07 |
Updated safety data from Phase 2b 003-A1 study of carfilzomib announced |
None |
| 2009-12-06 |
ImmunoGen reports encouraging clinical data of IMGN901 |
None |
| 2009-12-06 |
Positive final data from Phase 2 study of ISTODAX presented |
None |
| 2009-12-06 |
Dabigatran etexilate offers effective therapy to prevent recurrent VTE |
None |
| 2009-12-06 |
Bortezomib can improve control of GVHD and immune system recovery |
None |
| 2009-12-05 |
Investigators to discuss data presentations on carfilzomib inhibitor at ASH Annual Meeting |
None |
| 2009-12-05 |
Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI |
None |
| 2009-12-04 |
Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting |
None |
| 2009-12-04 |
Results from Phase III pivotal study of FIRMAGON presented |
None |
| 2009-12-04 |
Pfizer to present study findings from its expanded breast cancer portfolio |
None |
| 2009-12-04 |
Preclinical data of Curis' HSP 90 inhibitor published |
None |
| 2009-12-04 |
Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN |
None |
| 2009-12-04 |
Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel |
None |
| 2009-12-04 |
Genzyme announces reopening of enrollment in its Pompe disease ATAP program |
None |
| 2009-12-03 |
Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial |
None |
| 2009-12-03 |
Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial |
None |
| 2009-12-03 |
iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference |
None |
| 2009-12-03 |
Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist |
None |
| 2009-12-03 |
Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial |
None |
| 2009-12-03 |
Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC |
None |
| 2009-12-03 |
Tripep receives approval to extend ChronVac-C study |
None |
| 2009-12-03 |
More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented |
None |
| 2009-12-03 |
European Phase III clinical trial of budesonide MMX completes patient enrollment |
None |
| 2009-12-02 |
Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study |
None |
| 2009-12-02 |
FDA grants Fast Track designation for AEterna Zentaris' perifosine |
None |
| 2009-12-02 |
Genta to supply Ganite for new CF clinical trial |
None |
| 2009-12-02 |
Sepracor to present clinical study data of STEDESA at the 2009 AES meeting |
None |
| 2009-12-02 |
New data demonstrating the strength of Novartis' hematology portfolio to be presented |
None |
| 2009-12-02 |
University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration |
None |
| 2009-12-02 |
Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting |
None |
| 2009-12-02 |
Roche announces results of phase III taspoglutide study in diabetes patients |
2 |
| 2009-12-02 |
Results from second Phase III placebo controlled study of EXPAREL announced |
4 |
| 2009-12-02 |
Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics |
None |
| 2009-12-02 |
New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented |
None |
| 2009-12-02 |
Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting |
None |
| 2009-12-02 |
Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118 |
None |
| 2009-12-01 |
CRO to run CEL-SCI's upcoming Phase III clinical trial |
None |
| 2009-12-01 |
Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting |
None |
| 2009-12-01 |
Palatin Technologies issued U.S. patent covering its lead heart failure drug candidate |
None |
| 2009-12-01 |
Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat |
None |
| 2009-12-01 |
Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed |
5 |
| 2009-12-01 |
Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials |
None |
| 2009-12-01 |
StemCyte concludes exclusive license and commercialization agreement with Academia Sinica |
None |
| 2009-12-01 |
Amgen to present updated data on Nplate at the 2009 ASH meeting |
5 |
| 2009-12-01 |
Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences |
None |
| 2009-12-01 |
University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment |
None |
| 2009-12-01 |
ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro |
None |
| 2009-11-30 |
QRxPharma commences Phase 3 pivotal trial of MoxDuo IR |
None |
| 2009-11-30 |
Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials |
None |
| 2009-11-30 |
NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study |
None |
| 2009-11-30 |
Kiadis Pharma commences enrollment in multinational ATIR study |
None |
| 2009-11-30 |
NanoViricides announces filing of its quarterly report with the SEC |
None |
| 2009-11-30 |
Micromet to present new results from its blinatumomab study at the ASH meeting |
None |
| 2009-11-30 |
Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial |
None |
| 2009-11-27 |
Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment |
None |
| 2009-11-26 |
Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes |
None |
| 2009-11-25 |
Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting |
None |
| 2009-11-25 |
Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals |
None |
| 2009-11-25 |
Synexus recruits patients to study paediatric vaccine against rotavirus |
None |
| 2009-11-25 |
Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial |
None |
| 2009-11-25 |
Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting |
None |
| 2009-11-25 |
CHMP positive opinion for marketing ELONVA in Europe |
None |
| 2009-11-25 |
Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting |
None |
| 2009-11-25 |
EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody |
None |
| 2009-11-25 |
Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced |
None |
| 2009-11-25 |
Positive efficacy data from Phase 2 study of AEZS-108 announced |
None |
| 2009-11-24 |
OmniComm Systems chosen as Beardsworth's preferred EDC provider |
None |
| 2009-11-24 |
Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment |
1.5 |
| 2009-11-24 |
CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug |
None |
| 2009-11-24 |
Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study |
None |
| 2009-11-24 |
StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD |
None |
| 2009-11-23 |
Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients |
None |
| 2009-11-23 |
Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented |
None |
| 2009-11-23 |
Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD |
None |
| 2009-11-23 |
Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC |
4.3 |
| 2009-11-23 |
Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced |
1 |
| 2009-11-23 |
Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting |
None |
| 2009-11-23 |
Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma |
5 |
| 2009-11-23 |
Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial |
None |
| 2009-11-23 |
Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial |
None |
| 2009-11-23 |
Raptor Pharmaceutical announces results of NGX426 clinical trial |
5 |
| 2009-11-23 |
Enrollment for ongoing phase 2b trial of RG7128 announced |
None |
| 2009-11-23 |
Initiation of Phase I/IIa clinical trial of IL-7 announced |
None |
| 2009-11-20 |
POZEN commences enrollment in PA32540 phase 3 study |
None |
| 2009-11-20 |
Genta announces preliminary results from study of Genasense Injection for advanced melanoma |
None |
| 2009-11-20 |
EMEA's CHMP recommends approval of Merck's ELONVA |
None |
| 2009-11-20 |
Inovio Biomedical announces positive test results of its consensus influenza vaccines |
1 |
| 2009-11-20 |
Positive results from recently completed phase II clinical study of ToleroMune therapy announced |
None |
| 2009-11-20 |
Data from second positive pivotal study of PSD502 for treatment of PE presented |
None |
| 2009-11-20 |
Curemark begins enrolling patients in Phase III clinical trials for CM-AT |
None |
| 2009-11-19 |
Aegera Therapeutics commences AEG35156 Phase 2B study for AML |
None |
| 2009-11-19 |
Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A |
None |
| 2009-11-19 |
Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial |
None |
| 2009-11-19 |
Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE |
None |
| 2009-11-19 |
Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conference |
4 |
| 2009-11-19 |
AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate |
None |
| 2009-11-19 |
Final results from ImmuPharma's Phase IIb trial of LUPUZOR |
None |
| 2009-11-19 |
Data from Phase 1 safety study of SB-728-T announced |
None |
| 2009-11-19 |
Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics |
None |
| 2009-11-19 |
Once-a-day dosing clinical study of udenafil for erectile dysfunction completed |
5 |
| 2009-11-19 |
Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported |
None |
| 2009-11-18 |
Key findings from AstraZeneca's phase II studies of ticagrelor |
None |
| 2009-11-18 |
Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor |
None |
| 2009-11-18 |
Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC |
None |
| 2009-11-18 |
CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer |
None |
| 2009-11-18 |
Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles |
None |
| 2009-11-18 |
Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented |
None |
| 2009-11-18 |
Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference |
None |
| 2009-11-18 |
Clinical Data commences patient enrollment in Stedivaze Phase III trial |
None |
| 2009-11-18 |
New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented |
None |
| 2009-11-18 |
Positive results from REVIVE, a phase 3 pivotal study of avanafil announced |
None |
| 2009-11-18 |
Phase 2/3 study results of Genzyme's APB announced |
None |
| 2009-11-18 |
Pluristem’s PLX-PAD holds promise for critical limb ischemia |
None |
| 2009-11-18 |
Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions |
4 |
| 2009-11-18 |
Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced |
None |
| 2009-11-18 |
NeoPharm presents LE-DT Phase I data at the AACR conference |
1 |
| 2009-11-18 |
Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation |
None |
| 2009-11-18 |
On-going Phase 2b study conducted by Roche of ITMN-191 modified |
None |
| 2009-11-18 |
Review of the results of Phase 2b clinical trial on PASCAL announced |
None |
| 2009-11-18 |
Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease |
None |
| 2009-11-18 |
Phase III randomized clinical trial for Alpharadin to be commenced |
3 |
| 2009-11-18 |
Ongoing Phase 1 study results of XMT-1001 announced by Mersana Therapeutics |
None |
| 2009-11-17 |
Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen |
None |
| 2009-11-17 |
Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence |
None |
| 2009-11-17 |
Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers |
None |
| 2009-11-17 |
Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma |
5 |
| 2009-11-17 |
YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference |
None |
| 2009-11-17 |
Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study |
None |
| 2009-11-17 |
ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody |
None |
| 2009-11-17 |
Phase II clinical study to evaluate Nanocort commenced |
None |
| 2009-11-16 |
Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released |
None |
| 2009-11-16 |
Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate |
None |
| 2009-11-16 |
Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting |
None |
| 2009-11-16 |
Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma |
None |
| 2009-11-16 |
Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented |
None |
| 2009-11-16 |
Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint |
None |
| 2009-11-16 |
Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation |
None |
| 2009-11-16 |
Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced |
None |
| 2009-11-16 |
Aspirin doses have beneficial effects for patients with heart diorders: Study |
5 |
| 2009-11-16 |
New reversible blood thinner for angioplasty patients not superior over placebo |
None |
| 2009-11-16 |
Phase I clinical study for ETC-1002 commenced |
None |
| 2009-11-13 |
Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717 |
1 |
| 2009-11-13 |
Findings on the use of Traumeel S in children with mucositis undergoing SCT presented |
None |
| 2009-11-13 |
Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain |
None |
| 2009-11-13 |
Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released |
None |
| 2009-11-13 |
Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia |
None |
| 2009-11-13 |
Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS |
None |
| 2009-11-13 |
Adolor commences clinical testing of its oral mu opioid receptor antagonist |
None |
| 2009-11-12 |
Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference |
None |
| 2009-11-12 |
arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand |
None |
| 2009-11-12 |
Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference |
None |
| 2009-11-12 |
Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting |
None |
| 2009-11-12 |
Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting |
None |
| 2009-11-12 |
Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference |
None |
| 2009-11-11 |
Bend Memorial Clinic to begin Phase III lung cancer trial |
None |
| 2009-11-11 |
Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference |
None |
| 2009-11-11 |
Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA |
None |
| 2009-11-10 |
Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis |
5 |
| 2009-11-10 |
BioVex completes $70M financing to complete OncoVEX Phase III study |
None |
| 2009-11-10 |
Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer |
None |
| 2009-11-10 |
ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference |
None |
| 2009-11-09 |
Emisphere Technologies' key product developments and financial results for the third quarter of 2009 |
None |
| 2009-11-09 |
ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies |
None |
| 2009-11-09 |
Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor |
None |
| 2009-11-09 |
Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented |
None |
| 2009-11-09 |
C1-INH concentrate, an effective therapy to treat acute swelling attacks for HAE |
None |
| 2009-11-07 |
Halozyme Therapeutics announces results of its insulin variability study |
None |
| 2009-11-07 |
Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent |
None |
| 2009-11-06 |
GeoVax Labs announces financial results and operational update for the third quarter of 2009 |
None |
| 2009-11-06 |
Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented |
None |
| 2009-11-06 |
Novexel commences comparative study of NXL103 to oral linezolid |
None |
| 2009-11-05 |
Helix BioPharma completes enrollment in its Topical Interferon Alpha-2b ano-genital warts clinical program |
None |
| 2009-11-05 |
Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix |
4 |
| 2009-11-05 |
ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track |
None |
| 2009-11-05 |
Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology |
1 |
| 2009-11-05 |
Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference |
None |
| 2009-11-05 |
Patient enrollment in three late-stage clinical trials completed |
None |
| 2009-11-04 |
Warner Chilcott initiates phase III trial of erectile dysfunction drug udenafil |
None |
| 2009-11-04 |
Phase III study results on miconazole Lauriad presented by BioAlliance Pharma |
None |
| 2009-11-04 |
Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor |
None |
| 2009-11-04 |
Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting |
None |
| 2009-11-04 |
Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference |
1 |
| 2009-11-04 |
FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial |
None |
| 2009-11-04 |
ThromboGenics issues business update for the third-quarter of 2009 |
None |
| 2009-11-04 |
Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease |
2 |
| 2009-11-03 |
Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial |
None |
| 2009-11-03 |
EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference |
None |
| 2009-11-03 |
Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms |
None |
| 2009-11-03 |
Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome |
None |
| 2009-11-03 |
Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint |
None |
| 2009-11-03 |
AMRI receives $750,000 milestone payment from Bristol-Myers Squibb |
None |
| 2009-11-03 |
Phase 1 study of STX107 for Fragile X syndrome begins |
None |
| 2009-11-03 |
Interim data from Schering-Plough's narlaprevir Phase IIa study |
5 |
| 2009-11-03 |
NUVIGIL improves wakefulness in patients with excessive sleepiness associated with shift work disorder |
None |
| 2009-11-02 |
BioVex publishes OncoVEX (GM-CSF) Phase 2 study results |
None |
| 2009-11-02 |
Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients |
None |
| 2009-11-02 |
Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy |
None |
| 2009-11-02 |
Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis |
None |
| 2009-11-02 |
EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study |
1 |
| 2009-11-02 |
Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study |
None |
| 2009-11-02 |
Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor |
None |
| 2009-11-02 |
Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients |
None |
| 2009-11-02 |
NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics |
None |
| 2009-11-02 |
LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark |
None |
| 2009-11-02 |
Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients |
None |
| 2009-11-02 |
BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients |
None |
| 2009-11-02 |
HGS and GSK announce results from phase III clinical trials of BENLYSTA |
None |
| 2009-11-02 |
BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus |
None |
| 2009-11-02 |
Gilead Sciences to present Viread Phase III clinical trial data |
None |
| 2009-11-02 |
Vertex Pharmaceuticals announces study results of telaprevir-based regimen |
None |
| 2009-11-02 |
Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study |
None |
| 2009-10-31 |
Amgen publishes Phase 3 study results of Aranesp |
None |
| 2009-10-31 |
Shire to present key data on ADHD treatments at national psychiatric meeting |
None |
| 2009-10-31 |
Shire announces Phase IIIb study results of Daytrana |
None |
| 2009-10-31 |
New study results of INTUNIV presented at a major psychiatric medical meeting |
None |
| 2009-10-31 |
Schering-Plough receives FDA complete response letter regarding PEGINTRON |
None |
| 2009-10-31 |
Quintiles and Eisai partner to develop potential oncology products |
None |
| 2009-10-31 |
NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis |
None |
| 2009-10-31 |
Data from multiple clinical and preclinical studies evaluating Hematide announced |
None |
| 2009-10-30 |
Bayer HealthCare's Phase II study results of imaging agent florbetaben |
None |
| 2009-10-30 |
Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial |
None |
| 2009-10-30 |
Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV |
5 |
| 2009-10-30 |
Updated results from Oncolytics Biotech's Phase II study of REOLYSIN presented at CTOS meeting |
None |
| 2009-10-30 |
Eisai reports global Phase III study results of eribulin mesylate |
5 |
| 2009-10-30 |
AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device |
None |
| 2009-10-30 |
Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition |
None |
| 2009-10-30 |
Studies demonstrate that investigational cancer vaccines show encouraging immune response rates |
5 |
| 2009-10-30 |
Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine |
None |
| 2009-10-30 |
VIVUS presents additional data on Qnexa Phase 3 trials |
None |
| 2009-10-29 |
Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate |
None |
| 2009-10-29 |
Promedior granted European Orphan Medicinal Product Designation for PRM-151 |
None |
| 2009-10-29 |
Interim safety review of LEVADEX completed by MAP Pharmaceuticals |
None |
| 2009-10-29 |
Positive results from Genta's Phase 3 trial of Genasense |
2.3 |
| 2009-10-29 |
Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia |
None |
| 2009-10-29 |
Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting |
None |
| 2009-10-29 |
Positive top-line results from Phase IIb clinical trial of cariprazine announced |
None |
| 2009-10-29 |
Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial |
None |
| 2009-10-29 |
Roche discloses the results of first Phase III clinical study using Taspoglutide |
2 |
| 2009-10-29 |
CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress |
None |
| 2009-10-28 |
Advaxis to enroll patients in Phase II clinical trial of cervical dysplasia following IRB approval |
None |
| 2009-10-28 |
New data from CIMZIA WELCOME trial to be presented at the ACG meeting |
None |
| 2009-10-28 |
Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule |
None |
| 2009-10-28 |
Report on different approaches to reduce Phase II attrition |
None |
| 2009-10-28 |
Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients |
None |
| 2009-10-28 |
Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity |
None |
| 2009-10-28 |
Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin |
None |
| 2009-10-28 |
Data from Phase II clinical trial of NKTR-118 presented |
None |
| 2009-10-28 |
Recruitment of Phase II trial of TB-402 completed ahead of schedule |
None |
| 2009-10-28 |
POZEN announces Phase I study results of PA65020 |
None |
| 2009-10-28 |
Mirafit fbcx reduces human body absorption of consumed fat |
3.6 |
| 2009-10-27 |
Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting |
None |
| 2009-10-27 |
Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders |
None |
| 2009-10-27 |
NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study |
None |
| 2009-10-27 |
First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial |
None |
| 2009-10-27 |
Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation |
None |
| 2009-10-27 |
Interim results from FREEDOM study announced by NxStage Medical |
None |
| 2009-10-27 |
ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial |
None |
| 2009-10-27 |
Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound |
None |
| 2009-10-27 |
Positive results from Phase II clinical trial of INT-747 announced |
None |
| 2009-10-27 |
Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study |
None |
| 2009-10-27 |
PolyMedix completes second successful clinical study of PMX-60056 |
5 |
| 2009-10-27 |
Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials |
None |
| 2009-10-27 |
Phase 2 clinical study of PEG-Interferon lambda commenced |
None |
| 2009-10-27 |
LX211 may become the first approved oral treatment for modifying the course of uveitis |
None |
| 2009-10-27 |
Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting |
None |
| 2009-10-27 |
New data from efficacy study of CIMZIA in Crohn's disease patients presented |
None |
| 2009-10-27 |
Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients |
None |
| 2009-10-27 |
New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI |
None |
| 2009-10-27 |
Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer |
None |
| 2009-10-26 |
Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting |
None |
| 2009-10-26 |
ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans |
None |
| 2009-10-26 |
Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated |
None |
| 2009-10-26 |
Results from Phase I dose-escalation study of AT-101 announced |
3 |
| 2009-10-26 |
Cel Sci completes its production facility for Multikine Phase III clinical trial |
None |
| 2009-10-26 |
UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009 |
None |
| 2009-10-26 |
Santarus to present results from two investigator-initiated studies with ZEGERID at 2009 ACG meeting |
None |
| 2009-10-26 |
Dexmedetomidine can reduce pain when removing a tube from the airway of critically ill patients |
None |
| 2009-10-26 |
Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave |
5 |
| 2009-10-24 |
CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI |
None |
| 2009-10-24 |
Updated data on XL184 study in patients with glioblastoma multiforme presented |
3 |
| 2009-10-24 |
TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601 |
None |
| 2009-10-23 |
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets |
None |
| 2009-10-23 |
In vitro activity results of Cem-101 against gram-positive organisms to be presented |
None |
| 2009-10-23 |
TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients |
None |
| 2009-10-23 |
Affymax to make multiple presentations on preclinical and clinical data of Hematide |
5 |
| 2009-10-23 |
Positive results from Phase 2 clinical trial of ARX-03 announced |
None |
| 2009-10-22 |
KemPharm commences KP106 Phase 1 clinical trial for ADHD |
None |
| 2009-10-22 |
Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor |
None |
| 2009-10-22 |
PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial |
None |
| 2009-10-22 |
Pharmos announces results of its Phase 2b Dextofisopam trial |
None |
| 2009-10-22 |
Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference |
5 |
| 2009-10-22 |
Sosei Group announces Phase III trials update on NVA237 and QVA149 |
None |
| 2009-10-22 |
ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve |
None |
| 2009-10-22 |
Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab |
None |
| 2009-10-22 |
Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab |
None |
| 2009-10-22 |
Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin |
None |
| 2009-10-22 |
Study compares effects of clin-BPO 2.5% and clin-BPO 5% on epidermal functions |
None |
| 2009-10-22 |
New findings from ADVANCE clinical trial presented |
None |
| 2009-10-22 |
Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma |
None |
| 2009-10-22 |
Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients |
None |
| 2009-10-21 |
Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial |
None |
| 2009-10-21 |
Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain |
4.5 |
| 2009-10-21 |
CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting |
None |
| 2009-10-21 |
Celsion completes patient enrollment in its global Phase III ThermoDox trial |
None |
| 2009-10-21 |
Delcath Systems completes its pivotal Phase III Metastatic Melanoma Trial enrollment |
None |
| 2009-10-21 |
New results from ADVANCE provide important insights to reduce diabetes complications |
5 |
| 2009-10-21 |
Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis |
None |
| 2009-10-21 |
Genzyme commences patient enrollment in Genz-112638 phase 3 trials |
None |
| 2009-10-21 |
MediWound reports positive results from phase III Debrase trial for treating burns |
None |
| 2009-10-21 |
AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines |
None |
| 2009-10-20 |
Positive results from KAI Pharmaceuticals' pain therapeutic program |
None |
| 2009-10-20 |
Tarsa Therapeutics receives license for Phase III oral calcitonin program |
None |
| 2009-10-20 |
Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program |
None |
| 2009-10-20 |
Targacept presents data from Phase 2b clinical trial of TC-5214 |
None |
| 2009-10-20 |
Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec |
None |
| 2009-10-20 |
Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis |
None |
| 2009-10-20 |
Repligen completes patient treatment in its Phase 3 RG1068 clinical trial |
None |
| 2009-10-20 |
SIMPONI treatment results in greater inhibition of structural damage in arthritis patients |
None |
| 2009-10-20 |
Elan and Biogen Idec to present TYSABRI study data at ACG meeting |
None |
| 2009-10-20 |
Trial collaborators present results from Prime-Boost HIV Vaccine Clinical Trial |
None |
| 2009-10-20 |
AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials |
None |
| 2009-10-20 |
Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study |
None |
| 2009-10-20 |
NicOx presents data on its phase 3 naproxcinod study at the ACR meeting |
None |
| 2009-10-20 |
Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study |
None |
| 2009-10-20 |
Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting |
5 |
| 2009-10-20 |
Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA |
None |
| 2009-10-20 |
Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients |
None |
| 2009-10-20 |
Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma |
None |
| 2009-10-20 |
Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia |
None |
| 2009-10-20 |
Positive results from Transave's Phase II ARIKACE clinical trials |
None |
| 2009-10-19 |
UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis |
None |
| 2009-10-19 |
Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase |
None |
| 2009-10-19 |
Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial |
None |
| 2009-10-19 |
Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study |
None |
| 2009-10-19 |
New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis |
None |
| 2009-10-19 |
Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis |
None |
| 2009-10-19 |
Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting |
None |
| 2009-10-19 |
Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout |
None |
| 2009-10-19 |
Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris |
None |
| 2009-10-19 |
XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease |
None |
| 2009-10-19 |
Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada |
None |
| 2009-10-19 |
Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis |
None |
| 2009-10-19 |
Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer |
None |
| 2009-10-19 |
NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference |
None |
| 2009-10-19 |
Angiochem announces results of Phase 1 /2 clinical trials of ANG1005 |
None |
| 2009-10-19 |
Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study |
None |
| 2009-10-19 |
Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology |
None |
| 2009-10-19 |
FDA grants marketing approval for Elitek |
None |
| 2009-10-15 |
China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer |
3 |
| 2009-10-15 |
Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD |
None |
| 2009-10-15 |
Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC |
None |
| 2009-10-15 |
Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial |
None |
| 2009-10-15 |
pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit |
None |
| 2009-10-15 |
Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL |
None |
| 2009-10-15 |
Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings |
None |
| 2009-10-15 |
Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial |
None |
| 2009-10-14 |
FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial |
None |
| 2009-10-14 |
Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial |
None |
| 2009-10-14 |
EMEA grants ArQule's ARQ 197 orphan drug designation |
None |
| 2009-10-14 |
Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer |
None |
| 2009-10-14 |
Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine |
None |
| 2009-10-14 |
Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis |
None |
| 2009-10-14 |
Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes |
None |
| 2009-10-14 |
AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial |
None |
| 2009-10-13 |
Positive results from Alkermes' ALKS 33 clinical trials announced |
None |
| 2009-10-13 |
Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121 |
None |
| 2009-10-13 |
Sequella receives Phase 1 SBIR grant for developing SQ641 |
None |
| 2009-10-13 |
Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis |
None |
| 2009-10-12 |
Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009 |
None |
| 2009-10-12 |
Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference |
None |
| 2009-10-12 |
Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study |
None |
| 2009-10-12 |
Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada |
None |
| 2009-10-12 |
NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36 |
None |
| 2009-10-12 |
Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical |
None |
| 2009-10-12 |
Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118 |
None |
| 2009-10-12 |
NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth |
None |
| 2009-10-12 |
Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma |
None |
| 2009-10-12 |
NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients |
None |
| 2009-10-11 |
World’s first engineered T cell receptor trial opens with new cellular therapy for HIV |
None |
| 2009-10-09 |
Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug |
None |
| 2009-10-09 |
Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR |
None |
| 2009-10-09 |
Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial |
None |
| 2009-10-08 |
Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients |
None |
| 2009-10-08 |
Keryx Biopharmaceuticals commences Phase 2 clinical study evaluating KRX-0401 for Chronic Lymphocytic Leukemia |
None |
| 2009-10-08 |
Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development |
None |
| 2009-10-08 |
Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration |
None |
| 2009-10-07 |
Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia |
None |
| 2009-10-07 |
Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN |
None |
| 2009-10-07 |
Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis |
None |
| 2009-10-07 |
Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection |
None |
| 2009-10-07 |
Pharmaceutical companies gearing up for cancer vaccine trials following FDA draft guidance |
None |
| 2009-10-07 |
Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone |
None |
| 2009-10-07 |
Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis |
None |
| 2009-10-07 |
Early Phase II clinical trial for RK-023 to treat androgenetic alopecia |
None |
| 2009-10-06 |
Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced |
None |
| 2009-10-06 |
US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B |
None |
| 2009-10-06 |
AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology |
None |
| 2009-10-06 |
Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced |
None |
| 2009-10-06 |
Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug |
None |
| 2009-10-06 |
PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies |
None |
| 2009-10-06 |
OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer |
5 |
| 2009-10-06 |
EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS |
5 |
| 2009-10-06 |
ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference |
None |
| 2009-10-05 |
ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer |
None |
| 2009-10-05 |
Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC |
None |
| 2009-10-05 |
VIVUS to present data on Qnexa at The Obesity Society meeting |
None |
| 2009-10-05 |
Phase 3 clinical study results of Ketotransdel topical cream to be presented |
None |
| 2009-10-05 |
Preclinical study results of AVL-181 protease inhibitor presented |
5 |
| 2009-10-05 |
Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer |
5 |
| 2009-10-05 |
Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting |
None |
| 2009-10-05 |
Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis |
None |
| 2009-10-05 |
Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma |
None |
| 2009-10-05 |
Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia |
None |
| 2009-10-05 |
GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia |
None |
| 2009-10-05 |
Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released |
None |
| 2009-10-05 |
Genentech announces two Phase III study results of Lucentis |
5 |
| 2009-10-03 |
Xcellerex and Itero collaborate in production of an undisclosed therapeutic protein |
None |
| 2009-10-03 |
Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009 |
None |
| 2009-10-03 |
Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate |
None |
| 2009-10-03 |
Clinical study data of Thymosin beta 4 presented |
None |
| 2009-10-03 |
Avexa's ATC Phase III study concludes |
None |
| 2009-10-03 |
Interim results of Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine clinical trials announced |
None |
| 2009-10-03 |
KYTHERA Biopharmaceuticals presents its two Phase 2 clinical study results |
None |
| 2009-10-03 |
Phase 1b clinical trial results of PEG-Interferon lambda to be presented |
5 |
| 2009-10-03 |
Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study |
None |
| 2009-10-03 |
Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight |
None |
| 2009-10-03 |
NIH awards Titan $7.6M grant for Probuphine clinical development |
None |
| 2009-10-02 |
Preliminary Phase 2 study results of Plicera drug released |
None |
| 2009-10-01 |
Orexigen's Empatic Phase 2b results demonstrate weight loss |
None |
| 2009-10-01 |
Catalyst Pharmaceutical Partners to continue development of CPP-109 drug |
None |
| 2009-10-01 |
Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption |
None |
| 2009-10-01 |
Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody |
None |
| 2009-10-01 |
Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer |
None |
| 2009-10-01 |
Phase 1 clinical trial to test safety and activity of human MAB launched in India |
None |
| 2009-10-01 |
Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer |
None |
| 2009-10-01 |
Imthera Medical receives Ethics Committee clearance to start human clinical trials in Belgium |
None |
| 2009-10-01 |
Resverlogix RVX-208 exceeds expectations in Phase 1b/2a clinical trial |
None |
| 2009-10-01 |
Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting |
None |
| 2009-10-01 |
Update from BioCryst Pharmaceuticals regarding intravenous peramivir |
None |
| 2009-10-01 |
Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis |
None |
| 2009-10-01 |
Welichem announces filing of clinical trial application with Health Canada |
None |
| 2009-09-30 |
MacuSight's clinical development update on its proprietary ocular sirolimus product |
None |
| 2009-09-30 |
Amicus Therapeutics to initiate Phase 1 study of AT2220 |
None |
| 2009-09-30 |
Phase III clinical trial results demonstrate effectiveness of spinosad suspension |
None |
| 2009-09-30 |
Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial |
None |
| 2009-09-30 |
Polymedix commences Phase 1B study of novel anticoagulant reversing agent |
None |
| 2009-09-30 |
Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma |
3.7 |
| 2009-09-30 |
Results from Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients announced |
4 |
| 2009-09-30 |
AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review |
None |
| 2009-09-29 |
Vitae receives 11Beta-HSD-1 program milestone payment from Boehringer Ingelheim |
None |
| 2009-09-29 |
NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury |
None |
| 2009-09-29 |
pSivida reports interim results of human PK study of Iluvien |
None |
| 2009-09-29 |
Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies |
None |
| 2009-09-29 |
Acrux reports Phase III trial results evaluating AXIRON for testosterone deficiency |
5 |
| 2009-09-29 |
Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine |
None |
| 2009-09-29 |
International Medica Foundation sponsors rotavirus vaccine trial in Ghana |
None |
| 2009-09-28 |
Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests |
5 |
| 2009-09-28 |
NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis |
None |
| 2009-09-28 |
Halozyme Therapeutics announces Phase 1 clinical study to assess three insulin analogs |
None |
| 2009-09-28 |
Phase 2 clinical trial results of IMO-2055 announced |
None |
| 2009-09-27 |
Investigational vaccine regimen 31% effective in preventing HIV infection |
None |
| 2009-09-26 |
Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor |
1 |
| 2009-09-26 |
Morphotek announces preliminary data from Phase II trial of farletuzumab |
None |
| 2009-09-25 |
Dyax to present an update of its clinical development programs |
None |
| 2009-09-25 |
NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801 |
None |
| 2009-09-25 |
US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension |
None |
| 2009-09-25 |
Phase III PLATO study proves that ticagrelor is more effective than clopidogrel |
3 |
| 2009-09-25 |
Results from COGENT clinical trial presented at TCT symposium |
None |
| 2009-09-25 |
Huachansu may slow cancer progression |
None |
| 2009-09-25 |
Partial success reported in the Phase 3 trial of HIV/AIDS vaccine |
None |
| 2009-09-24 |
CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma |
None |
| 2009-09-24 |
Karo Bio announces clinical phase II results of thyroid hormone analog eprotirome |
None |
| 2009-09-24 |
Phase II study of OPAXIO to be revealed |
None |
| 2009-09-24 |
Phase III efficacy trial of two AIDS vaccine candidates shows promise |
5 |
| 2009-09-24 |
ThromboGenics completes enrollment for MIVI-TRUST clinical trial |
None |
| 2009-09-24 |
CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment |
None |
| 2009-09-24 |
MicroDose initiates Phase 1 clinical trial investigating the pharmacokinetics of atropine inhalation |
None |
| 2009-09-24 |
Enrollment for pSivida's pilot FAVOR clinical study commences |
None |
| 2009-09-24 |
FDA endorses Covidien's REMS program for EXALGO tablets |
None |
| 2009-09-24 |
Results of Phase III clinical trial of HIV vaccine released |
None |
| 2009-09-24 |
Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer |
5 |
| 2009-09-24 |
Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome |
None |
| 2009-09-23 |
Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury |
None |
| 2009-09-23 |
Results of Phase 3 CRYSTAL study of mCRC patients announced |
5 |
| 2009-09-23 |
FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic |
4 |
| 2009-09-23 |
Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia |
None |
| 2009-09-23 |
Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced |
None |
| 2009-09-23 |
Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced |
None |
| 2009-09-23 |
Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging |
5 |
| 2009-09-23 |
Drug trial for OSI-906 begins |
None |
| 2009-09-23 |
CERE-110 trial to stop the progression of Alzheimer's disease |
None |
| 2009-09-23 |
BioMarin commences PEG-PAL Phase 2 clinical trial for phenylketonuria |
5 |
| 2009-09-22 |
Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa |
None |
| 2009-09-22 |
NicOx announces publication of blood pressure results from the phase 3 study of naproxcinod |
None |
| 2009-09-22 |
Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium |
None |
| 2009-09-22 |
IRSF announces funding of new clinical study with disease-modifying therapy treatment for Rett syndrome |
None |
| 2009-09-22 |
Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy |
None |
| 2009-09-22 |
Bayer's regorafenib showed 50% stabilization rate in RCC patients |
None |
| 2009-09-22 |
Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors |
None |
| 2009-09-21 |
Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent |
None |
| 2009-09-21 |
Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete |
5 |
| 2009-09-21 |
Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic |
None |
| 2009-09-21 |
Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation |
None |
| 2009-09-21 |
Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials |
None |
| 2009-09-21 |
Perrigo purchases KV Pharmaceutical's ANDA for clindamycin phosphate and benzoyl peroxide gel |
None |
| 2009-09-21 |
Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial |
None |
| 2009-09-21 |
Phase II trial of Impax Pharmaceuticals' Parkinson’s disease drug candidate successful |
None |
| 2009-09-21 |
FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis |
3 |
| 2009-09-21 |
Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus |
1 |
| 2009-09-21 |
Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit |
None |
| 2009-09-21 |
PROLOR Biotech initiates Phase I clinical trial of its human growth hormone drug candidate |
None |
| 2009-09-21 |
Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris |
None |
| 2009-09-21 |
NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development |
5 |
| 2009-09-21 |
Amgen announces results of Phase 3 trial in the treatment of bone metastases |
None |
| 2009-09-19 |
Millennium's sNDA for VELCADE granted priority review by the FDA |
None |
| 2009-09-18 |
Results from the BLOSSOM trial announced by Arena Pharmaceuticals |
None |
| 2009-09-18 |
Eastern Europe, Latin America and Asia are new regions for clinical trials |
None |
| 2009-09-17 |
Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent |
None |
| 2009-09-17 |
China SFDA approves clinical trial of China Aoxing's abuse resistant opioid drug |
None |
| 2009-09-17 |
Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment |
1 |
| 2009-09-17 |
Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced |
None |
| 2009-09-17 |
Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress |
None |
| 2009-09-17 |
Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug |
None |
| 2009-09-17 |
Genentech releases Phase III PRIMA study findings |
None |
| 2009-09-17 |
Bioheart's MARVEL Phase II/III clinical trial successful |
None |
| 2009-09-17 |
ULURU reports Altrazeal clinical trial results |
None |
| 2009-09-16 |
VOICE clinical study for testing the efficacy of two HIV prevention strategies |
None |
| 2009-09-16 |
Amgen to present its four Phase 3 clinical trial results |
None |
| 2009-09-16 |
FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma |
None |
| 2009-09-16 |
CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval |
5 |
| 2009-09-16 |
Celsion's DIGNITY clinical trial aired on Good Morning America |
None |
| 2009-09-16 |
Medivir presented preclinical data from its cathepsin K inhibitor program at the ASBMR meeting |
None |
| 2009-09-16 |
Savient updates on its Biologics License Application with the FDA for KRYSTEXXA |
None |
| 2009-09-16 |
Pros and cons of HIV treatments in developing countries |
None |
| 2009-09-16 |
Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC |
5 |
| 2009-09-16 |
Phase III EXTEND trial results of pixantrone announced |
None |
| 2009-09-16 |
Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD |
None |
| 2009-09-16 |
NIMH awards Genomas an SBIR Grant to develop MRI DNA biomarkers for neuropsychiatric disease |
None |
| 2009-09-16 |
NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process |
None |
| 2009-09-15 |
FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX |
None |
| 2009-09-15 |
Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003 |
None |
| 2009-09-15 |
Hyperion enrolls first patient in HPN-100 investigational compound clinical trial |
None |
| 2009-09-15 |
Palatin Technologies to announce clinical trial results of PL-3994 |
None |
| 2009-09-15 |
Extension study data on Fampridine-SR drug |
None |
| 2009-09-15 |
Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program |
None |
| 2009-09-15 |
Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus |
None |
| 2009-09-15 |
KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent |
None |
| 2009-09-15 |
Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced |
None |
| 2009-09-15 |
Phase III results of Lauriad presented at the 49th Annual ICAAC |
None |
| 2009-09-15 |
Phase II VICTOR-E1 clinical study results reported |
None |
| 2009-09-15 |
NanoBio presents preclinical data of NB-201 for treating burn wounds at the 2009 ICAAC |
None |
| 2009-09-15 |
Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress |
None |
| 2009-09-15 |
NovaBay's Aganocide compounds effective against multidrug-resistant bacteria |
None |
| 2009-09-15 |
Rib-X and NIAID collaborate to develop an antibiotic treatment for N. gonorrhoeae |
None |
| 2009-09-15 |
Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis |
None |
| 2009-09-15 |
Phase 2b trial of Mpex's Aeroquin with PARI Pharma's eFlow Nebulizer System successful |
None |
| 2009-09-15 |
Phase I results of Tobira's TBR-652 CCR5 antagonist for the treatment of HIV |
None |
| 2009-09-15 |
FDA provides a complete response letter for Digestive Care's PANCRECARB |
None |
| 2009-09-14 |
BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis |
None |
| 2009-09-14 |
Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353 |
5 |
| 2009-09-14 |
Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting |
None |
| 2009-09-14 |
Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced |
None |
| 2009-09-14 |
Clinical studies reveal treatment with pirfenidone is safe and well-tolerated |
None |
| 2009-09-14 |
Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium |
None |
| 2009-09-14 |
Cytrx initiates tamibarotene and TRISENOX combination dose escalation study |
None |
| 2009-09-14 |
Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate |
None |
| 2009-09-14 |
Altair announces positive Phase I results for AIR645 in treating asthma |
None |
| 2009-09-14 |
Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug |
None |
| 2009-09-14 |
Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients |
None |
| 2009-09-14 |
Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results |
None |
| 2009-09-14 |
Protalix Biotherapeutics reports completion of its Phase III trial of prGCD |
None |
| 2009-09-14 |
Phase 1 results of CTP-347 presented |
None |
| 2009-09-14 |
Preliminary results of Phase 2b clinical trial of AZ-104 announced by Alexza Pharmaceuticals |
None |
| 2009-09-14 |
ARIAD to complete its Phase 3 SUCCEED trial following DMS recommendation |
None |
| 2009-09-14 |
Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress |
None |
| 2009-09-14 |
Final results of SAPHRIS clinical study released |
None |
| 2009-09-14 |
Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed |
None |
| 2009-09-14 |
GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer |
5 |
| 2009-09-14 |
Phase 3 results of TARGET 1 and TARGET 2 clinical trials released |
None |
| 2009-09-14 |
Phase IIa clinical data of EHT 0202 released |
None |
| 2009-09-14 |
Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz |
1 |
| 2009-09-14 |
Clinical data on CXA-101 to be presented at ICAAC |
None |
| 2009-09-14 |
Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC |
None |
| 2009-09-14 |
Clinical data emphasizing on efficacy and potency of torezolid to be presented |
None |
| 2009-09-14 |
Phase III clinical trial results of DAR-31 published |
None |
| 2009-09-14 |
Data from Phase III clinical trial of TYSABRI presented at ECTRIMS |
None |
| 2009-09-14 |
Influenza patients treated with Tamiflu has higher survival rates |
None |
| 2009-09-14 |
Phase IIa trial results of panobacumab released |
None |
| 2009-09-14 |
FOCUS 1 and FOCUS 2 clinical trial results released |
None |
| 2009-09-14 |
NIAID conducts human clinical trials of 2009 H1N1 influenza vaccines |
None |
| 2009-09-14 |
Oral NKTR-118 has low risk for mediating significant drug-drug interactions |
None |
| 2009-09-14 |
Phase 2 MS clinical trial data continues to show durable reductions in relapse rate |
None |
| 2009-09-13 |
AVONEX results in fewer injection site reactions, according to a clinical study |
None |
| 2009-09-11 |
Genspera to commence G-202 Phase I trial following FDA approval |
None |
| 2009-09-11 |
Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems |
None |
| 2009-09-11 |
Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs |
None |
| 2009-09-11 |
Delcath Systems to continue Phase III clinical trial |
None |
| 2009-09-11 |
Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product |
None |
| 2009-09-11 |
First patient enrolled in Phase 2b RADAR clinical trial |
None |
| 2009-09-11 |
Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented |
None |
| 2009-09-11 |
Update on Prolindac clinical development plan provided by Access Pharmaceuticals |
None |
| 2009-09-11 |
Merck update on the status of telcagepant clinical development programs |
4 |
| 2009-09-11 |
Positive results from Mpex' Phase 2b clinical trial with Aeroquin |
None |
| 2009-09-10 |
Phase II human clinical trial of Exsulin commences |
None |
| 2009-09-10 |
Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate |
5 |
| 2009-09-10 |
Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis |
4 |
| 2009-09-10 |
NIH provides Inviragen second major grant to develop a dengue vaccine |
None |
| 2009-09-10 |
Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases |
5 |
| 2009-09-10 |
Human neural stem cells to treat Pelizaeus-Merzbacher Disease |
None |
| 2009-09-10 |
GI Company's Phase II study demonstrates safety of rhITF oral spray formulation |
None |
| 2009-09-10 |
FDA approves Ascenta's IND for AT-406 multi-IAP antagonist |
None |
| 2009-09-10 |
Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine |
None |
| 2009-09-10 |
Quatrx' second phase 3 study of ospemifene tablets provides positive results |
None |
| 2009-09-10 |
Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology |
None |
| 2009-09-10 |
Protox' Phase 2 study of PRX302 for treating BPH provides positive results |
None |
| 2009-09-10 |
Acorda Therapeutics announces Phase 3 Fampridine-SR trial findings |
1 |
| 2009-09-10 |
Affymax to complete Hematide Phase 3 clinical study by the end of 2009 |
None |
| 2009-09-10 |
Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections |
None |
| 2009-09-10 |
Galapagos starts new clinical trial for GLPG0259 |
None |
| 2009-09-10 |
Patient enrollment completed in Phase 2b clinical trial for Pyridorin |
None |
| 2009-09-09 |
American Medical News examines clinical trials outsourcing |
None |
| 2009-09-09 |
Phase II trial of ANA598 commenced by Anadys Pharmaceuticals |
None |
| 2009-09-09 |
Protox Therapeutics to present TRIUMPH clinical study update |
None |
| 2009-09-09 |
VIVUS' Phase 3 studies find Qnexa effective in tackling obesity |
5 |
| 2009-09-09 |
INSPIRE Phase I/IIa study data to be presented at ICAAC |
None |
| 2009-09-09 |
Synexus on track to double its clinical trial capacity in South Africa, opens two new research centres in Pretoria |
None |
| 2009-09-09 |
Patient enrollment completed in Phase II clinical trial of bavituximab |
None |
| 2009-09-09 |
Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1 |
None |
| 2009-09-09 |
Preliminary Phase 3 clinical study results of T-Pred released |
None |
| 2009-09-09 |
Can-Fite's Phase II clinical study of CF101 provides positive results |
None |
| 2009-09-09 |
Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma |
None |
| 2009-09-09 |
Study to test efficacy of lapatinib in advanced hepatocellular carcinoma |
None |
| 2009-09-09 |
Phase III trials for CS-8958 neuraminidase inhibitor successful |
5 |
| 2009-09-08 |
Valeant develops an acne drug with a low concentration of BPO combined with clindamycin |
None |
| 2009-09-08 |
Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics |
None |
| 2009-09-08 |
Opexa Therapeutics releases Phase IIb TERMS clinical study results |
None |
| 2009-09-08 |
DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant |
None |
| 2009-09-08 |
Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics |
None |
| 2009-09-08 |
Third human clinical trial of LigoCyte's norovirus vaccine started |
4.8 |
| 2009-09-08 |
Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION |
None |
| 2009-09-05 |
Securities class action lawsuit filed against Repros Therapeutics |
None |
| 2009-09-04 |
Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials |
None |
| 2009-09-04 |
Dilafor Phase II clinical trial completes |
None |
| 2009-09-04 |
OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor |
None |
| 2009-09-04 |
Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response |
5 |
| 2009-09-04 |
Two ongoing Phase 2 clinical trials of CPX-351 to be showcased |
None |
| 2009-09-04 |
Results of Phase 2 rheumatoid arthritis clinical trial announced |
None |
| 2009-09-03 |
Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12 |
None |
| 2009-09-03 |
Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine |
None |
| 2009-09-03 |
Study reports a potential new investigational therapy for skin cancer |
None |
| 2009-09-03 |
First swine-flu vaccine trials reveal strong immune response |
None |
| 2009-09-03 |
CORD I phase III clinical trial results of XIAFLEX published |
5 |
| 2009-09-03 |
New clinical trials to address the effectiveness of antimicrobial drugs |
None |
| 2009-09-03 |
Interim Phase II data of Cotara reveals signs of efficacy in GBM patients |
None |
| 2009-09-03 |
GDC-0449 inhibits the Hedgehog signaling pathway |
4 |
| 2009-09-03 |
Avastin increases survival rates in recurrent glioblastoma affected patients |
None |
| 2009-09-02 |
Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass |
5 |
| 2009-09-02 |
FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies |
None |
| 2009-09-02 |
Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon |
4.2 |
| 2009-09-02 |
FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML |
None |
| 2009-09-02 |
Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp |
None |
| 2009-09-02 |
PROTECT clinical study aimed at the assessment of rolofylline effects |
None |
| 2009-09-02 |
Positive results from second pivotal phase III trial for Lodotra |
None |
| 2009-09-02 |
PLATO study reveals that ticagrelor reduces the rate of cardiovascular events |
4.5 |
| 2009-09-02 |
High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO |
4 |
| 2009-09-01 |
GS-101 effective in inhibiting and regressing corneal neovascularisation |
None |
| 2009-09-01 |
Cimzia approved for treating adult patients with rheumatoid arthritis |
None |
| 2009-09-01 |
TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful |
1 |
| 2009-09-01 |
Results of the first pivotal Phase III trial with pimavanserin in patients with PDP announced |
None |
| 2009-09-01 |
Biovail announces Phase III trial results for pimavanserin |
None |
| 2009-09-01 |
Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation |
None |
| 2009-09-01 |
Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study |
None |
| 2009-08-31 |
Stanford University starts recruiting participants for swine flu vaccine clinical trial |
None |
| 2009-08-31 |
Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation |
None |
| 2009-08-31 |
Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial |
None |
| 2009-08-31 |
Sonomax Hearing Healthcare completes Phase II trials of a delivery mechanism that inflates a V3 earplug successfully |
None |
| 2009-08-31 |
BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product |
None |
| 2009-08-31 |
Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program |
None |
| 2009-08-31 |
Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology |
None |
| 2009-08-31 |
RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients |
None |
| 2009-08-30 |
Initial results of the CURRENT-OASIS 7 clinical trial due for release |
None |
| 2009-08-29 |
Global Markets Direct's new report on Spinal Fusion Clinical Trial Analysis |
None |
| 2009-08-29 |
Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009 |
None |
| 2009-08-29 |
New report on product clinical trials conducted by Tissue Sealants manufacturers |
None |
| 2009-08-29 |
Global Markets Direct's new report pertains to product clinical trials being carried out by Repair and Restorative Materials manufacturers |
None |
| 2009-08-29 |
Two human biomarker assays that play a key role in the early detection of kidney damage provide assistance in drug development |
None |
| 2009-08-28 |
Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic |
None |
| 2009-08-28 |
Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress |
None |
| 2009-08-28 |
Research And Markets' report on product clinical trials carried out by Spinal Non-Fusion manufacturers |
None |
| 2009-08-28 |
Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments |
None |
| 2009-08-28 |
Forest Laboratories announces phase 3 trial results for roflumilast |
2 |
| 2009-08-28 |
Forest Laboratories to host a conference call for discussing the results of Daxas Phase III clinical trials |
None |
| 2009-08-28 |
Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan |
None |
| 2009-08-28 |
Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma |
None |
| 2009-08-27 |
Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies |
None |
| 2009-08-27 |
QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules |
5 |
| 2009-08-27 |
Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds |
None |
| 2009-08-27 |
BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results |
None |
| 2009-08-26 |
Quality test for Guardian Technologies International's Signature Mapping TBDx system completed |
None |
| 2009-08-26 |
New interactive web site launched by DATATRAK |
None |
| 2009-08-26 |
EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale |
None |
| 2009-08-26 |
Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6 |
None |
| 2009-08-26 |
Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete |
None |
| 2009-08-26 |
Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period |
None |
| 2009-08-26 |
Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL |
5 |
| 2009-08-26 |
Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia |
None |
| 2009-08-26 |
Phase III RE-LY study results to be presented at the European Society of Cardiology Congress |
4 |
| 2009-08-26 |
Washington Post examines development of vaccine for food borne intestinal illness |
None |
| 2009-08-26 |
Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003 |
None |
| 2009-08-25 |
Venlafaxine alleviates depressive symptoms |
None |
| 2009-08-25 |
Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial |
None |
| 2009-08-25 |
Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech Ueno |
None |
| 2009-08-25 |
Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin |
None |
| 2009-08-25 |
Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system |
None |
| 2009-08-25 |
Phase I/II trial of Amphinex uses photochemical internalisation approach |
None |
| 2009-08-24 |
Orphan drug status granted to BioCancell's BC-819 drug |
None |
| 2009-08-24 |
Retigabine's Phase IIa clinical trial preliminary results announced |
None |
| 2009-08-24 |
Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS |
None |
| 2009-08-24 |
CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US |
None |
| 2009-08-24 |
Profibrix raises funds for clinical and preclinical development |
None |
| 2009-08-24 |
Biovail enters into an agreement with Santhera to develop and market JP-1730/fipamezole drug |
None |
| 2009-08-22 |
Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug |
None |
| 2009-08-21 |
Endologix publishes abdominal aortic aneurysm treatment trial results online |
None |
| 2009-08-21 |
NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer |
None |
| 2009-08-20 |
Peplin completes four-week enrolment phase for REGION-Ib trial |
None |
| 2009-08-20 |
InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191 |
None |
| 2009-08-19 |
Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia |
5 |
| 2009-08-19 |
Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease |
None |
| 2009-08-19 |
Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine |
None |
| 2009-08-19 |
Arzoxifene phase 3 study results reported by Lilly |
None |
| 2009-08-19 |
Hard to Treat Diseases' swine flu clinical trials in progress |
1 |
| 2009-08-19 |
Low-dose estrogen effective for metastatic breast cancer |
None |
| 2009-08-19 |
Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced |
None |
| 2009-08-19 |
Amarex joins OmniComm Systems' CRO Preferred Program |
None |
| 2009-08-18 |
4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat) |
None |
| 2009-08-18 |
Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer |
None |
| 2009-08-17 |
Human Genome Sciences achieves systemic lupus goals with candidate drug |
None |
| 2009-08-17 |
Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia |
None |
| 2009-08-14 |
New immune therapy for kidney cancer tested |
5 |
| 2009-08-13 |
First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial |
None |
| 2009-08-13 |
Antigenics’ Oncophage cancer vaccine trial starts enrolling patients |
3 |
| 2009-08-12 |
Study looks at imipramine in the treatment of irritable bowel syndrome |
5 |
| 2009-08-12 |
Cannabis Science reports on future plans for cannabis drug trials |
None |
| 2009-08-12 |
Investigational, orally-inhaled therapy effective in treating migraines |
None |
| 2009-08-12 |
Researchers respond to concerns about international insulin drug trial |
None |
| 2009-08-12 |
Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer |
None |
| 2009-08-11 |
Britain's first swine flu vaccine trials start |
None |
| 2009-08-11 |
New type of anti-clotting drug called Apixaban |
None |
| 2009-08-11 |
Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer |
None |
| 2009-08-11 |
Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis |
None |
| 2009-08-11 |
Gene Signal publishes phase I data on GS-101 for diseases of the eye |
None |
| 2009-08-11 |
Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s |
None |
| 2009-08-11 |
Additional trial to be conducted for KYNAPID under FDA special protocol agreement |
None |
| 2009-08-10 |
Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial |
4 |
| 2009-08-10 |
Nanoviricides anti-herpes drug candidate reduces viral load by 99.99% |
2 |
| 2009-08-09 |
Cost-effectiveness of Cetuximab in metastatic colorectal cancer |
None |
| 2009-08-06 |
Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine |
None |
| 2009-08-06 |
Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus |
None |
| 2009-08-05 |
Baxter completes production of batches of CELVAPAN A/H1N1 pandemic vaccine |
2 |
| 2009-08-04 |
Clinical trial to test gene therapy for Alzheimer’s disease |
None |
| 2009-08-04 |
Accelerating the development of new cancer drugs |
None |
| 2009-08-04 |
Women and minorities under-represented in trials |
None |
| 2009-08-03 |
Metformin associated with reduced risk of pancreatic cancer in diabetics |
None |
| 2009-08-02 |
Tarceva shown to extend survival in advanced non-small cell lung cancer when used after initial chemo |
None |
| 2009-07-31 |
Medicago announces positive results for H1N1 pandemic vaccine candidate |
None |
| 2009-07-28 |
New drug promises to reduce damage from a heart attack |
2 |
| 2009-07-28 |
Deferoxamine could help diabetics heal wounds |
None |
| 2009-07-27 |
Seattle Genetics starts Brentuximab Vedotin retreatment trial |
None |
| 2009-07-22 |
H1N1 death toll doubles over last month; first vaccine trial begins |
None |
| 2009-07-22 |
NIAID to launch 2009 H1N1 influenza vaccine trials |
None |
| 2009-07-22 |
Hepatitis C infection: Treatment options equally effective, likelihood of success known early on |
None |
| 2009-07-21 |
Miglustat shows promise for cystic fibrosis |
4.5 |
| 2009-07-21 |
Onchocerciasis elimination feasible with ivermectin treatment |
None |
| 2009-07-20 |
South Africa launches HIV/AIDS vaccine trial |
None |
| 2009-07-19 |
Preliminary findings in Phase IIA trial point to natural compound NIC5-15's potential in Alzheimer's disease |
None |
| 2009-07-19 |
TGF beta blocker prevents epilepsy following traumatic brain injury |
3 |
| 2009-07-17 |
Thalidomide does not improve survival in small cell lung cancer |
None |
| 2009-07-16 |
Sunitinib shows promise for advanced kidney cancer patients with poor prognosis |
None |
| 2009-07-16 |
Improved bone healing with osteoporosis drug teriparatide |
None |
| 2009-07-15 |
Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV |
None |
| 2009-07-12 |
Results from trials of DHA in Alzheimer's and age-related cognitive decline |
None |
| 2009-07-07 |
Thiarabine shows promise for rheumatoid arthritis |
None |
| 2009-07-07 |
Multaq approved for atrial fibrillation by FDA |
None |
| 2009-07-07 |
The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women |
None |
| 2009-07-07 |
Artemisinin-based combination therapy for treating uncomplicated malaria |
None |
| 2009-07-06 |
PATRICIA trial shows HPV vaccine effective in prevention of cervical lesions |
None |
| 2009-07-06 |
Antidepressants aid electroconvulsive therapy in treating severe depression |
5 |
| 2009-07-02 |
Question marks on credibility of some published clinical trials |
4.5 |
| 2009-07-01 |
Moxidectin being tested for onchocerciasis |
2 |
| 2009-06-28 |
Golimumab shows promise for rheumatoid arthritis |
5 |
| 2009-06-28 |
Inhaled growth hormone safe for children deficient in this key protein |
3 |
| 2009-06-23 |
Clinical trial raises hope for Australian diabetics to be insulin free |
4.5 |
| 2009-06-18 |
Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma |
None |
| 2009-06-18 |
Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise |
1 |
| 2009-06-18 |
Globe and Mail examines GlaxoSmithKline's RTS,S malaria vaccine trials in Kenya |
None |
| 2009-06-17 |
Cholesterol-lowering statin drugs do not lower risk of pneumonia in seniors |
None |
| 2009-06-17 |
Trial of new ‘combo’ treatment for hepatitis C |
None |
| 2009-06-16 |
Topical fluorouracil may improve appearance of aging skin |
5 |
| 2009-06-16 |
Pneumococcal vaccine effective in preventing severe pneumonia |
5 |
| 2009-06-09 |
Antiretroviral therapy earlier yields better clinical outcomes |
3 |
| 2009-06-09 |
Novel diabetes treatment Syncria (albiglutide) improves glucose control and reduces weight |
2.7 |
| 2009-06-09 |
Botox injections can help overactive bladders sufferers |
5 |
| 2009-06-09 |
Cisplatin doubles lung cancer survival time in mice |
None |
| 2009-06-05 |
HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients |
None |
| 2009-06-05 |
Tuberculosis booster vaccine trials to begin next month In South Africa |
None |
| 2009-06-04 |
Experimental drug five times more effective against MDR-TB than conventional therapy |
None |
| 2009-06-02 |
Trial results show better survival for gallbladder and bile duct cancer |
None |
| 2009-06-01 |
Study to evaluate ‘Active Hexose Correlated Compound’ and the swine flu virus |
None |
| 2009-06-01 |
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer |
None |
| 2009-06-01 |
Citalopram no more effective than a placebo for children with autism spectrum disorders |
None |
| 2009-06-01 |
Bayer announces new data on novel anti-cancer compound |
None |
| 2009-06-01 |
Blood pressure drug reverses liver damage |
None |
| 2009-05-31 |
Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients |
None |
| 2009-05-31 |
Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer |
None |
| 2009-05-31 |
Blood-pressure medicine shown to reverse the effects of early-stage liver failure |
None |
| 2009-05-31 |
Catalyst Pharmaceutical Partners announces top-line results of CPP-109 phase II trial for cocaine addiction |
None |
| 2009-05-26 |
Zyflamend shows promise for prostate cancer |
5 |
| 2009-05-26 |
Abraxane prolongs survival in metastatic breast cancer |
None |
| 2009-05-26 |
Diabetes drug pioglitazone shows potential against multiple sclerosis |
5 |
| 2009-05-25 |
Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer |
None |
| 2009-05-22 |
Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer |
None |
| 2009-05-21 |
Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure |
None |
| 2009-05-21 |
ChemGenex’s Omacetaxine to be showcased in three oral oresentations at EHA |
None |
| 2009-05-20 |
Trial tests potential new angina treatment |
None |
| 2009-05-20 |
Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan |
None |
| 2009-05-17 |
Sodium channel-blocking agent shows promise as a potential treatment for cystic fibrosis |
None |
| 2009-05-17 |
Pirfenidone shows promise for idiopathic pulmonary fibrosis |
3 |
| 2009-05-17 |
Pregabalin shows potential as treatment for hot flashes |
3 |
| 2009-05-14 |
Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says |
None |
| 2009-05-12 |
Participants in antidepressant drug trials are atypical patients |
None |
| 2009-05-12 |
Schering-Plough starts patient enrollment in phase 3 trial for Acadesine |
None |
| 2009-05-07 |
Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's |
None |
| 2009-05-07 |
Amsterdam Molecular Therapeutics commences preregistration trial for Glybera |
None |
| 2009-05-06 |
Metoclopramide versus droperidol for extreme nausea, vomiting during pregnancy |
4 |
| 2009-05-04 |
New anticonvulsant compound prevents seizure progression in model of epilepsy |
None |
| 2009-04-30 |
A negative mGluR5 allosteric modulator shows efficacy in treating acute migraine attacks |
None |
| 2009-04-30 |
Histone deacetylase inhibitors show promise against head and neck cancer |
None |
| 2009-04-29 |
Pregabalin shows potential for restless legs syndrome - improves sleep |
None |
| 2009-04-29 |
Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment |
None |
| 2009-04-29 |
Many Black teens consider themselves victims of racial discrimination |
None |
| 2009-04-27 |
Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy |
None |
| 2009-04-27 |
Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells |
None |
| 2009-04-26 |
Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C |
None |
| 2009-04-26 |
New lidocaine-prilocaine spray may treat premature ejaculation |
1 |
| 2009-04-23 |
Trial of unique malaria vaccine candidate to begin |
None |
| 2009-04-22 |
Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma |
None |
| 2009-04-22 |
Seattle Genetics presents new data on antibody-drug conjugate |
None |
| 2009-04-22 |
FDA gives 'go ahead' for phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease |
None |
| 2009-04-22 |
AcelRx starts cancer breakthrough pain program |
None |
| 2009-04-22 |
AEterna Zentaris presents results for AEZS-112 in advanced cancer and lymphoma |
None |
| 2009-04-22 |
Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers |
None |
| 2009-04-22 |
Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer |
None |
| 2009-04-20 |
NanoBio starts clinical trial for adjuvanted intranasal flu vaccine |
4 |
| 2009-04-20 |
Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout |
None |
| 2009-04-20 |
Study looks at shikonin for human gastric adenocarcinoma |
None |
| 2009-04-20 |
Naltrexone appears to relieve fibromyalgia pain |
4.7 |
| 2009-04-15 |
Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness |
4 |
| 2009-04-15 |
Mycophenolate mofetil may be an alternative therapy for lupus nephritis |
None |
| 2009-04-14 |
Experimental insulin-like growth factor receptor inhibitor a clear clinical candidate for pancreatic cancer therapy |
None |
| 2009-04-14 |
Oral etoricoxib provides pain relief after surgery |
None |
| 2009-04-13 |
Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma |
None |
| 2009-04-12 |
Treatment for acid reflux does not improve asthma symptoms |
None |
| 2009-04-09 |
Serentis begins trial with first-in-class SRD441 for eczema |
None |
| 2009-04-09 |
Clinical trials for two compounds show promise in advanced prostate cancer |
None |
| 2009-04-09 |
Experimental drug lowers PSA levels |
None |
| 2009-04-08 |
New therapy for metastatic prostate cancer shows promise |
None |
| 2009-04-08 |
Trial of new biologic agent to treat psoriatic arthritis |
None |
| 2009-04-08 |
Intercell starts trial for Streptococcus pneumoniae vaccine candidate |
None |
| 2009-04-06 |
Experimental vaccine shows promise for the treatment of early lung cancer |
None |
| 2009-04-06 |
Celsion announces promising trial results for ThermoDox in breast cancer |
None |
| 2009-04-06 |
Avastin safe and effective at delaying tumor progression |
None |
| 2009-04-02 |
Is telmisartan effective in treating non-alcoholic steatohepatitis? |
None |
| 2009-04-02 |
Bionovo announces publication of positive phase 2 trial results for Menerba |
5 |
| 2009-04-02 |
Aerovance starts phase IIb clinical trial with Aerovant for uncontrolled asthma |
None |
| 2009-04-01 |
Sorafenib may help patients suffering from advanced portal hypertension |
None |
| 2009-04-01 |
Pharmaxis reaches milestone in cystic fibrosis trial |
None |
| 2009-03-31 |
ImQuest presents data on the anti-hepatitis B virus activity of Pyrimidinediones |
None |
| 2009-03-31 |
New smoking cessation drug varenicline tartrate shows promise in trials |
None |
| 2009-03-30 |
SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects |
None |
| 2009-03-30 |
Corthera's Relaxin in acute heart failure shows promising results |
None |
| 2009-03-30 |
Nile Therapeutics update on phase II CD-NP trial for acute heart failure |
None |
| 2009-03-29 |
New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography |
None |
| 2009-03-29 |
NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management |
None |
| 2009-03-29 |
Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients |
None |
| 2009-03-29 |
Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia |
None |
| 2009-03-29 |
ARCA biopharma presents data from phase 3 BEST trial of Gencaro |
None |
| 2009-03-29 |
Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes |
None |
| 2009-03-29 |
CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis |
None |
| 2009-03-29 |
CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism |
None |
| 2009-03-29 |
A comparative analysis of four beta blocker trials |
None |
| 2009-03-29 |
ArunA Biomedical to commercialize human embryonic stem cell derived mesenchymal cells |
None |
| 2009-03-29 |
Amicus Therapeutics presents positive results from phase 2 extension study of Amigal for Fabry disease |
None |
| 2009-03-29 |
RegeneRx reports phase II venous stasis trial results |
None |
| 2009-03-29 |
Positive phase 3 uveitis trial results for voclosporin |
None |
| 2009-03-29 |
Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments |
None |
| 2009-03-26 |
Oxycodone effective against shingles pain |
None |
| 2009-03-24 |
Rexahn Pharmaceuticals starts phase II pancreatic cancer trial |
None |
| 2009-03-24 |
Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes |
None |
| 2009-03-24 |
Orexo reports on efficacy study in allergic rhinitis with OX914 |
None |
| 2009-03-24 |
Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension |
None |
| 2009-03-24 |
Canadian researchers to launch clinical trial to determine efficacy of treating latent TB with four-month course of Rifampin |
None |
| 2009-03-24 |
Phase II clinical trial of tuberculosis vaccine candidate to begin next month in South Africa |
None |
| 2009-03-23 |
Review of probiotics in the treatment of Irritable Bowel Syndrome |
None |
| 2009-03-23 |
NEJM Letters respond to recent studies on malaria vaccines, treatments |
None |
| 2009-03-22 |
Cathepsin B increases apoptosis in fulminant hepatic failure |
None |
| 2009-03-20 |
SemBioSys Genetics announces clinical results with plant-produced insulin |
None |
| 2009-03-20 |
Potential colon cancer being tested |
None |
| 2009-03-17 |
Drug pactimibe does not appear to reduce progression of atherosclerosis |
None |
| 2009-03-17 |
Cephalon announces positive results from study of NUVIGIL in bipolar depression |
None |
| 2009-03-17 |
Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate |
None |
| 2009-03-16 |
Budesonide nasal wash shows promise for chronic rhinosinusitis |
4.5 |
| 2009-03-16 |
Trial of new combination treatment targeting hormone receptor-positive locally advanced breast cancer |
None |
| 2009-03-16 |
Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions |
None |
| 2009-03-16 |
Healthpoint intiates phase II clinical trial to evaluate effectiveness of HP802-247 in venous leg ulcers |
None |
| 2009-03-15 |
Nobilon's intranasal influenza vaccine begins phase I clinical development |
None |
| 2009-03-12 |
Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study |
None |
| 2009-03-12 |
Biothera receives approval to launch two lung cancer trials |
None |
| 2009-03-12 |
BioCis Pharma starts trial of novel topical drug for dermatology |
None |
| 2009-03-11 |
Rituximab may be effective in treating membranous nephropathy |
None |
| 2009-03-11 |
Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint |
5 |
| 2009-03-11 |
Rituximab useful for advanced indolent lymphoma |
None |
| 2009-03-10 |
Long-term effects of two common drugs for early Parkinson's similar |
None |
| 2009-03-05 |
Vaginal microbicide gel shows promise as HIV prevention method for women |
None |
| 2009-03-04 |
Rituximab reduces kidney inflammation in patients with severe lupus nephritis |
None |
| 2009-03-03 |
Pharmaxis announces NDA filing for Aridol |
None |
| 2009-03-03 |
Trial looks at telmisartan in treating non-alcoholic steatohepatitis |
None |
| 2009-03-03 |
Bionovo announces publication of positive trial results for Menerba |
None |
| 2009-03-03 |
Aerovance starts trial of Aerovant for uncontrolled asthma |
None |
| 2009-03-03 |
Type 1 diabetes patients sought for UT Southwestern clinical drug trial |
None |
| 2009-03-02 |
Angiogenesis inhibitors, study points to limitations, solutions |
None |
| 2009-03-02 |
Biphasic insulin provides significant improvements in more than 52,000 diabetic patients |
None |
| 2009-03-02 |
Chantix side effects no worse for people with history of depression |
2 |
| 2009-03-01 |
Experimental drug fampridine improves mobility for some MS patients |
5 |
| 2009-02-26 |
Lab tests show meropenem and clavulanate combination effective against drug-resistant TB bacteria |
1.5 |
| 2009-02-25 |
Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer |
None |
| 2009-02-24 |
Goserelin improves long-term survival in premenopausal women with early breast cancer |
None |
| 2009-02-23 |
Bavarian Nordic updates on breast cancer vaccine studies |
5 |
| 2009-02-22 |
Neuralstem's ALS trial on hold |
None |
| 2009-02-20 |
Questions of ethics and quality cloud globalization of clinical trials |
None |
| 2009-02-20 |
Optimizing dosage of blood-thinning drug warfarin |
None |
| 2009-02-20 |
Drug sodium phenylbutyrate could improve the memory of those with Alzheimer's disease |
None |
| 2009-02-18 |
Ondansetron shown to be a viable treatment option for opioid addiction |
5 |
| 2009-02-18 |
GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication |
None |
| 2009-02-16 |
Experimental antiarrhythmic drug dronedarone reduces death rate in patients with atrial fibrillation |
2 |
| 2009-02-16 |
New trial targets kidney cancer drug sorafenib in bladder cancer |
None |
| 2009-02-16 |
Avosentan shows prmoise for diabetic kidney disease |
None |
| 2009-02-15 |
Trial of Quadramet (153 Samarium-lexidronam) in combo with Velcade shows positive results |
None |
| 2009-02-11 |
Study on ustekinumab for treatment of psoriatic arthritis published |
None |
| 2009-02-11 |
Candesartan cilexetil reduces proteinuria in kidney disease patients |
4 |
| 2009-02-10 |
ViroPharma reports results of trial for Maribavir in bone marrow transplant patients |
None |
| 2009-02-08 |
Atorvastatin and lovastatin found to be ineffective for breast cancer prevention |
None |
| 2009-02-05 |
Study tests salsalate anti-inflammatory for poorly controlled type 2 diabetes |
None |
| 2009-02-05 |
Sangamo BioSciences starts trial of CCR5-ZFP therapeutic to treat HIV/AIDS |
None |
| 2009-02-05 |
Safinamide significantly improved motor function in patients with advanced Parkinson's disease |
4 |
| 2009-02-02 |
Fasudil could reduce risk of Alzheimer's |
None |
| 2009-02-02 |
Sedative dexmedetomidine may offer advantages over agents often used for sedation in ICU |
None |
| 2009-02-02 |
Antiepileptic drug vigabatrin may decrease spasms for infants with epilepsy |
None |
| 2009-02-02 |
Century old drug clofazimine shows potential for multiple sclerosis |
None |
| 2009-02-02 |
Infliximab after intestinal resective surgery may help prevent post-op Crohn's disease recurrence |
None |
| 2009-01-29 |
Study of cannabinoid medicine for pain found patients got 'high,' but effects not related to pain relief |
None |
| 2009-01-29 |
Leconotide, an investigative calcium channel blocker, shows potential as pain treatment |
None |
| 2009-01-27 |
Early treatment with rasagiline (Azilect) for Parkinson's best |
5 |
| 2009-01-23 |
Lisofylline drug improves type 2 insulin action; reduces harm of fat in preclinical study |
None |
| 2009-01-19 |
Cream containing tretinoin associated with death in clinical trial, but relationship does not appear causal |
5 |
| 2009-01-19 |
Pre-emptive treatment helped curtail skin toxicity with Panitumumab |
None |
| 2009-01-19 |
Combo malaria treatment dihydroartemisinin and piperaquine shows promise |
None |
| 2009-01-15 |
Algeta completes phase II trial with Alpharadin for treating bone metastases in advanced prostate cancer |
None |
| 2009-01-09 |
Discovery of better treatment for bacterial pneumonia |
5 |
| 2009-01-08 |
New nasal spray vaccine shown to be effective against botulism |
None |
| 2009-01-06 |
Active Hexose Correlated Compound shown to enhances immune system by increasing production of key dendritic cells |
None |
| 2009-01-06 |
Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program |
None |
| 2009-01-06 |
New drug being tested for Fragile X syndrome |
4 |
| 2009-01-06 |
Phase III studies of EXPAREL (DepoBupivacaine) from Pacira complete enrollment |
None |
| 2009-01-06 |
Clioquinol - gastrointestinal drug could become anti-aging treatment |
None |
| 2009-01-06 |
Nicotine gum effective for gradual smoking reduction and cessation |
None |
| 2009-01-06 |
Chimerix completes phase I study and starts phase II multi-dose trial for CMX001 |
None |
| 2009-01-06 |
Novel compound F15845 shows promise for angina |
None |
| 2009-01-06 |
Novel treatment option for obesity |
None |
| 2009-01-05 |
Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients |
None |
| 2009-01-05 |
Molecular insight into how a heart failure drug in clinical trials works |
None |
| 2009-01-05 |
Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2 |
None |
| 2009-01-01 |
Candesartan shown to be safe new therapy for genetic heart disease |
None |